Scenarios for the long‐term efficacy of amyloid‐targeting therapies in the context of the natural history of Alzheimer's disease
Alzheimer's & Dementia · 2024-09 · 20 (9) · 6374-6383
DOI: 10.1002/alz.14134 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 29.07.2024. Verfasst von Lars Lau Raket und 4 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIA NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Recent clinical trials of amyloid beta (Aβ)‐targeting therapies in Alzheimer's disease (AD) have demonstrated a clinical benefit over 18 months, but their long‐term impact on disease trajectory is not yet understood. We propose a framework for evaluating realistic long‐term scenarios. METHODS Results from recent phase 3 trials of Aβ‐targeting antibodies were integrated with an estimate of the long‐term patient‐level natural history trajectory of the Clinical Dementia Rating‐Sum of Boxes (CDR‐SB) score to explore realistic long‐term efficacy scenarios. RESULTS Three distinct long‐term efficacy scenarios were examined, ranging from conservative to optimistic. These extrapolations of positive phase 3 trials suggested treatments delayed onset of severe dementia by 0.3 to 0.6 years (conservative), 1.1 to 1.9 years (intermediate), and 2.0 to 4.2 years (optimistic). DISCUSSION Our study provides a common language for long‐term impact of disease‐modifying treatments. Our work calls for studies with longer follow‐up and results from early intervention trials to provide a comprehensive assessment of these therapies' true long‐term impact. Highlights We present long‐term scenarios of the efficacy of AD therapies. In this framework, scenarios are defined relative to the natural history of AD. Long‐term projections with different levels of optimism can be compared. It provides a common language for expressing beliefs about long‐term efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eli Lilly and Company, Indianapolis, Indiana, USA.
- Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden.
- Chambers-Grundy Center for Transformative Neuroscience, Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV), Las Vegas…
- Wallenberg Centre for Molecular and Translational Medicine and the Department of Psychiatry and Neurochemistry, University of Gothenburg, Huvudbyggnad Vasaparken, Universitetsplatsen 1, Gothenburg, Sweden.
- Department of Neurology, Institute of Memory and Alzheimer's Disease, AP-HP Sorbonne Université, Pitié-Salpêtrière Hospital, Paris, France.
- Sorbonne Université, INSERM U1127, Institut du Cerveau - ICM, Paris, France.
ORCID-Profile: Lars Lau Raket
Förderung
- NIGMS NIH HHS
- NIA NIH HHS
Zitieren
APA
Raket, L. L., Cummings, J., Moscoso, A., Villain, N., & Schöll, M. (2024). Scenarios for the long‐term efficacy of amyloid‐targeting therapies in the context of the natural history of Alzheimer's disease. Alzheimer's & Dementia, 20(9), 6374-6383. https://doi.org/10.1002/alz.14134
Vancouver
Raket LL, Cummings J, Moscoso A, Villain N, Schöll M. Scenarios for the long‐term efficacy of amyloid‐targeting therapies in the context of the natural history of Alzheimer's disease. Alzheimer's & Dementia. 2024;20(9):6374-6383. doi:10.1002/alz.14134
BibTeX
@article{Raket2024,
author = {Raket, Lars Lau and Cummings, Jeffrey and Moscoso, Alexis and Villain, Nicolas and Schöll, Michael},
title = {Scenarios for the long‐term efficacy of amyloid‐targeting therapies in the context of the natural history of Alzheimer's disease},
journal = {Alzheimer's & Dementia},
year = {2024},
volume = {20},
number = {9},
pages = {6374--6383},
doi = {10.1002/alz.14134}
}
EUVIMED